Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a significant addition to its drug pipeline with the acquisition of CT-95 from Link Immunotherapeutics, Inc. The asset is a mesothelin …
Context Therapeutics Acquires Promising Cancer Treatment Asset Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has announced that the national supply of cisplatin, a key cancer medication, now exceeds demand, ending a critical shortage that began …
FDA Announces End to National Shortage of Crucial Cancer Drug Cisplatin Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released new survey results highlighting persistent drug shortages in cancer treatment across the United States. While the availability of …
NCCN Survey Reveals Ongoing Cancer Drug Shortages Despite Improvements Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative cancer treatment, CT-0525. This therapy targets …
FDA Grants Fast Track Status to Carisma Therapeutics’ New Cancer Therapy Read More
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved blinatumomab (Blincyto, Amgen Inc.) for both adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative …
FDA Approves Blinatumomab for Advanced Leukemia Treatment Read More
PHILADELPHIA, PA — EpiVario Inc., a biotechnology firm specializing in neuroepigenetics to treat addiction disorders, announced a significant licensing deal with ReEngage Therapeutics. The agreement involves several of EpiVario’s small …
EpiVario Licenses Cancer-Fighting Compounds in Strategic Move Read More